Back
Novonesis AS Stock Price Chart
Sponsored
NVZMY
Sponsored
S&P Global: Private Equity Invests $36 Billion Into What?
Read More
Buy
58
NVZMY
Novonesis AS
Last Price:
58.86
Seasonality Move:
4.77%
7 Day Trial
ALL ACCESS PASS
$
7
Biden's Oil War: The Administration Is All-In on Green Energy.
Download Free Report- The current trend is moderately bullish and NVZMY is experiencing slight buying pressure.
Novonesis AS Price Chart Indicators
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 59.52 | Sell |
20-day SMA: | 59.38 | Sell |
50-day SMA: | 55.51 | Buy |
200-day SMA: | 49.48 | Buy |
8-day EMA: | 59.38 | Sell |
20-day EMA: | 58.82 | Buy |
50-day EMA: | 56.52 | Buy |
200-day EMA: | 52.04 | Buy |
Novonesis AS Technical Analysis Indicators
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | 1.03 | Buy |
Relative Strength Index (14 RSI): | 53.2 | Buy |
Chaikin Money Flow: | 1724 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (56.96 - 60.52) | Buy |
Bollinger Bands (100): | (50.62 - 57.2) | Buy |
Novonesis AS Technical Analysis
Mar 14 | Mar 15 | Mar 18 | Mar 19 | Mar 20 | Mar 21 | Mar 22 | Mar 25 | Mar 26 | Mar 27 | |
---|---|---|---|---|---|---|---|---|---|---|
Mar | ||||||||||
14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | 27 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
Technical Analysis for Novonesis AS Stock
Is Novonesis AS Stock a Buy?
- Novonesis AS share price is 58.85 while NVZMY 8-day simple moving average is 59.52, which is a Sell signal.
- The stock price of NVZMY is 58.85 while Novonesis AS 20-day SMA is 59.38, which makes it a Sell.
- Novonesis AS 50-day simple moving average is 55.51 while NVZMY share price is 58.85, making it a Buy technically.
- NVZMY stock price is 58.85 and Novonesis AS 200-day simple moving average is 49.48, creating a Buy signal.
NVZMY Technical Analysis vs Fundamental Analysis
Buy
58
Novonesis AS (NVZMY)
is a Buy
Is Novonesis AS a Buy or a Sell?
-
Novonesis AS stock is rated a Buy
The current Novonesis AS [NVZMY] share price is $58.85. The Score for NVZMY is 58, which is 16% above its historic median score of 50, and infers lower risk than normal.
Novonesis AS Stock Info
Market Cap:
27.33B
Price in USD:
58.85
Share Volume:
5.67K
Novonesis AS 52-Week Range
52-Week High:
61.86
52-Week Low:
38.75
Buy
58
Novonesis AS (NVZMY)
is a Buy
Novonesis AS Share Price Forecast
-
What is the Novonesis AS stock price today?
The Novonesis AS stock price is 58.85 USD today. -
Will NVZMY stock go up or go down?
Novonesis AS> share price is forecast to RISE/FALL based on technical indicators -
Is Novonesis AS overvalued?
According to simple moving average, exponential moving average, oscillators, and other technical indicators, Novonesis AS is not overvalued.
Is Novonesis AS Stock a Buy?
- Novonesis AS share price is 58.85 while NVZMY 8-day exponential moving average is 59.38, which is a Sell signal.
- The stock price of NVZMY is 58.85 while Novonesis AS 20-day EMA is 58.82, which makes it a Buy.
- Novonesis AS 50-day exponential moving average is 56.52 while NVZMY share price is 58.85, making it a Buy technically.
- NVZMY stock price is 58.85 and Novonesis AS 200-day simple moving average is 52.04, creating a Buy signal.
Technical Analysis of Novonesis AS
Should I short Novonesis AS stock?
- NVZMY Moving Average Covergence Divergence (MACD) indicator is 1.03, suggesting Novonesis AS is a Buy
- Novonesis AS Relative Strength Index (RSI) is 53.2, which suggest Novonesis AS is overbought
- The Bollinger Bands (25) for Novonesis AS is (56.96 - 60.52), which suggest Novonesis AS is a Buy
- The Bollinger Bands (100) for Novonesis AS is (50.62 - 57.2), which suggest Novonesis AS is a Buy
* Novonesis AS stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.